IDXX — IDEXX Laboratories Inc. stock price and chart

IDXX

IDEXX Laboratories Inc.Stock · HealthcareNasdaq-100 0.2% · S&P 500 Equal Weight 0.2% · Nasdaq Composite 0.10% · S&P 500 0.06% · Russell 1000 0.06% · Russell 3000 0.06% · US Stock Market 0.06% · MSCI World 0.05% · MSCI ACWI 0.05%

$504.70-0.36%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

100.0200.0300.0400.0500.0600.0700.0010.0M20.0M$504.70

2026-09-11

Price$504.70

MA20$556.20

MA50$610.36

Vol3.0M

What would $1,000 invested in IDXX be worth today? →

IDXX returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $504.70
Change YTD: -25.40%
Next earnings: Nov 2, 2026
Market cap: 39.8B2016-09 10.1B2026-09 39.8B+293.3% over the window
Enterprise value: 40.1B
Shares outstanding: 78.8M2016-06 89.5M2026-06 78.8M-12.0% over the window
52W low: $500.61
52W high: $769.98
From 52W high: -34.45%
From 52W low: +0.82%
52W range: 2%
Beta: 1.54

Volume

Rel volume: 0.68×
30D volume: 586.9K
30D $ vol: 327.5M

Fundamentals

Sales (ttm): 4.6B2016-06 1.7B2026-06 4.6B+169.4% over the window
Sales/share: $57.802016-06 $18.882026-06 $57.80+206.2% over the window
EPS (ttm): $14.222016-06 $2.212026-06 $14.22+543.3% over the window
FCF (ttm): 1.3B2016-06 220.2M2026-06 1.3B+469.5% over the window
FCF/share: $15.922016-06 $2.462026-06 $15.92+547.3% over the window
Book value/share: $20.472016-06 -$0.102026-06 $20.47-21318.0% over the window
Net margin: 25.03%2016-06 11.9%2026-06 25.0%+109.6% over the window
ROE: 70.67%2016-09 390.2%2026-06 70.7%-81.9% over the window
ROA: 33.11%2016-06 13.6%2026-06 33.1%+144.3% over the window
Debt / equity: 0.19×2019-12 3.942026-06 0.19-95.3% over the window
Current ratio: 1.172016-06 1.002026-06 1.17+17.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +12.78%2025-06-30 → 2026-06-304B → 4.6B (+12.8% total)+9.02%2023-06-30 → 2026-06-303.5B → 4.6B (+29.6% total)+8.37%2021-06-30 → 2026-06-303B → 4.6B (+49.5% total)+10.42%2016-06-30 → 2026-06-301.7B → 4.6B (+169.4% total)
Net income: +15.64%2025-06-30 → 2026-06-30985.7M → 1.1B (+15.6% total)+12.92%2023-06-30 → 2026-06-30791.4M → 1.1B (+44.0% total)+9.38%2021-06-30 → 2026-06-30727.8M → 1.1B (+56.6% total)+18.90%2016-06-30 → 2026-06-30201.8M → 1.1B (+464.8% total)
FCF: +59.97%2025-06-30 → 2026-06-30784.3M → 1.3B (+59.9% total)+28.38%2023-06-30 → 2026-06-30592.8M → 1.3B (+111.6% total)+12.56%2021-06-30 → 2026-06-30694.3M → 1.3B (+80.7% total)+19.00%2016-06-30 → 2026-06-30220.2M → 1.3B (+469.5% total)
Shares: -1.53%2025-06-30 → 2026-06-3080M → 78.8M (-1.5% total)-1.73%2023-06-30 → 2026-06-3083M → 78.8M (-5.1% total)-1.53%2021-06-30 → 2026-06-3085.1M → 78.8M (-7.4% total)-1.27%2016-06-30 → 2026-06-3089.5M → 78.8M (-12.0% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +18.48%2025-06-30 → 2026-06-30$12.00 → $14.22 (+18.5% total)+14.68%2023-06-30 → 2026-06-30$9.43 → $14.22 (+50.8% total)+11.14%2021-06-30 → 2026-06-30$8.38 → $14.22 (+69.6% total)+20.46%2016-06-30 → 2026-06-30$2.21 → $14.22 (+543.3% total)
Sales/share: +14.53%2025-06-30 → 2026-06-30$50.47 → $57.80 (+14.5% total)+10.93%2023-06-30 → 2026-06-30$42.33 → $57.80 (+36.5% total)+10.05%2021-06-30 → 2026-06-30$35.81 → $57.80 (+61.4% total)+11.84%2016-06-30 → 2026-06-30$18.88 → $57.80 (+206.2% total)
FCF/share: +62.46%2025-06-30 → 2026-06-30$9.80 → $15.92 (+62.4% total)+30.63%2023-06-30 → 2026-06-30$7.14 → $15.92 (+123.0% total)+14.30%2021-06-30 → 2026-06-30$8.16 → $15.92 (+95.1% total)+20.54%2016-06-30 → 2026-06-30$2.46 → $15.92 (+547.3% total)
Book value/share: +12.26%2025-06-30 → 2026-06-30$18.23 → $20.47 (+12.3% total)+15.81%2023-06-30 → 2026-06-30$13.18 → $20.47 (+55.3% total)+18.43%2021-06-30 → 2026-06-30$8.79 → $20.47 (+133.0% total)n/a
Price: -21.78%2025-09-11 → 2026-09-11$645.16 → $504.70 (-21.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+2.29%2023-09-11 → 2026-09-11$471.51 → $504.70 (+7.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.83%2021-09-10 → 2026-09-11$681.61 → $504.70 (-26.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+16.45%2016-09-09 → 2026-09-11$109.97 → $504.70 (+358.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -21.78%2025-09-11 → 2026-09-11$645.16 → $504.70 (-21.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+2.29%2023-09-11 → 2026-09-11$471.51 → $504.70 (+7.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.83%2021-09-10 → 2026-09-11$681.61 → $504.70 (-26.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+16.45%2016-09-09 → 2026-09-11$109.97 → $504.70 (+358.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 35.5×2016-09 47.222026-09 34.88-26.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 27.3×2016-09 30.322026-09 27.25-10.1% over the window
Fwd P/E: 32.0×
P/S (ttm)Market cap ÷ TTM revenue.: 8.7×2016-09 5.842026-09 8.73+49.6% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 24.7×2016-09 184.272026-09 24.65-86.6% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 31.7×2016-09 40.082026-09 31.69-20.9% over the window
EV/EBITDA (fy): 24.9×
EV/Sales (ttm): 8.8×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 3.15%2016-06 2.2%2026-06 3.1%+40.0% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 78.8M ÷ 80.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.53%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.53%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($42.9B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 1.53%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.2B) ÷ today's market cap ($39.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.96%2016-06 2.6%2026-06 2.9%+11.9% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.2B + TTM dividends $0) ÷ today's market cap ($39.8B). Same caveat as the cash buyback yield.: 2.96%2016-06 2.6%2026-06 2.9%+11.9% over the window

Vs own 10Y history

P/E: 0th
P/OI: 0th
P/S: 25th
P/B: 8th
P/FCF: 0th

Bar = where today’s multiple sits in IDXX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-0.36%

-4.65%

-11.55%

-9.54%

YTD

-25.40%

-20.89%

-26.37%

Financial statements

Open full IDXX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

IDEXX Laboratories Inc. (IDXX) trades at $504.70 with a live price and an interactive chart covering 35+ years of daily price history, plus key valuation metrics. ChartRow also publishes IDXX’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full IDXX financial statements →

IDXX — IDEXX Laboratories Inc. price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · windows as of 2026-09-11

Financial statements

Related Healthcare